Boston Scientific Corp Dossier
Qualitative Analysis
Business overview
Boston Scientific Corporation (NYSE: BSX) is a global developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties. The company operates through two primary reportable segments: Cardiovascular and MedSurg. Its diverse portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological, and urological diseases and conditions. Key product lines include the WATCHMAN Left Atrial Appendage Closure Device, the FARAPULSE pulsed-field ablation system, and various intravascular imaging, vessel preparation, and neuromodulation technologies. Boston Scientific operates in over 170 locations globally, serving healthcare providers and patients worldwide.
Research as of 29 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Driving commercial execution and clinical evidence generation for the FARAPULSE Pulsed Field Ablation platform and WATCHMAN Left Atrial Appendage Closure technologies to maintain market leadership amid rising competition.
Expected impact: Sustain double-digit growth in electrophysiology and structural heart segments, expanding the addressable patient population globally.
Targeting continuous operational improvements and cost efficiencies to expand adjusted operating margins.
Expected impact: Supports sustained double-digit adjusted EPS growth and strong free cash flow conversion.
Investing €75 million to expand research and development capabilities in Galway, Ireland.
Expected impact: Accelerates the development of next-generation medical technologies and expands global R&D capacity.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Provides a scaled entry into mechanical thrombectomy and neurovascular segments, expanding Boston Scientific's portfolio to address vascular diseases with minimal product overlap.
Financial impact: Expected to be $0.06 to $0.08 dilutive to adjusted EPS in the first full year, neutral to slightly accretive in the second year, and increasingly accretive thereafter.
Acquisition of the eCoin System (implantable tibial nerve stimulation device) to expand into high-growth adjacencies for the Urology business.
Financial impact: Expected to have an immaterial impact on adjusted EPS in 2026 and to be more dilutive on a GAAP basis due to amortization and transaction charges.
Expands neuromodulation offerings for chronic pain through Nalu's minimally invasive peripheral nerve stimulation (PNS) system.
Financial impact: Upfront cash payment of $533 million for remaining equity ($600 million on a 100% basis). Expected to be immaterial to adjusted EPS in 2026, slightly accretive in 2027, and increasingly accretive thereafter.